060IC - From Guidelines to Practice: Applying Genetics and Genomics in Urologic Cancer Management
Monday, May 18, 2026 7:30 AM to 9:30 AM · 2 hr. (America/New_York)
152B
Instructional Course
Oncology: General
Information
Course Description: This interactive, case-based course explores the role of germline genetics in urologic cancers and how genetic alterations can inform precision oncology. Participants will receive a concise yet comprehensive review of hereditary cancer syndromes involving the kidneys, adrenal glands, upper urinary tract, bladder, and prostate. The course will cover genetic risk assessment, diagnosis, and treatment strategies across a range of hereditary urologic cancers.
We will review current NCCN and AUA guidelines for genetic evaluation and discuss practical approaches to identifying patients appropriate for genetic testing and counseling. Additional topics include interpretation of genetic and genomic test results, components of informed consent, and best practices in collaborating with genetic counselors.
By the end of this course, participants will be equipped to:
- Recognize patients at increased risk for hereditary urologic cancers.
- Understand and apply current clinical guidelines for genetic evaluation.
- Confidently interpret test results to guide treatment decisions.
- Integrate genetic and genomic information into routine clinical workflows to improve patient care and access to precision therapies.
Learning Objective 1: Explain the essential components of genetic risk assessment, genetic counseling, and informed consent in the context of genetic testing for urologic cancers.
Learning Objective 2: Interpret key elements of genetic test reports, including variant classification, variant allele frequency, gene penetrance, biomarkers, and clinical actionability.
Learning Objective 3: Identify guideline-based criteria for germline genetic testing in men with prostate cancer. Understand the clinical implications of genetic findings for prostate cancer screening, risk stratification, and management of both localized and advanced disease.
Learning Objective 4: Describe the genetic basis, clinical presentation, testing indications, and cancer risks associated with hereditary kidney cancer syndromes. Understand how specific genetic alterations inform surveillance and treatment strategies in syndromes such as von Hippel-Lindau (VHL) and hereditary leiomyomatosis and renal cell cancer (HLRCC).
Learning Objective 5: Recognize the genetic basis, tumor characteristics, and associated cancer risks of Lynch syndrome, and apply this knowledge to optimize the evaluation and management of patients with upper tract urothelial carcinoma.
We will review current NCCN and AUA guidelines for genetic evaluation and discuss practical approaches to identifying patients appropriate for genetic testing and counseling. Additional topics include interpretation of genetic and genomic test results, components of informed consent, and best practices in collaborating with genetic counselors.
By the end of this course, participants will be equipped to:
- Recognize patients at increased risk for hereditary urologic cancers.
- Understand and apply current clinical guidelines for genetic evaluation.
- Confidently interpret test results to guide treatment decisions.
- Integrate genetic and genomic information into routine clinical workflows to improve patient care and access to precision therapies.
Learning Objective 1: Explain the essential components of genetic risk assessment, genetic counseling, and informed consent in the context of genetic testing for urologic cancers.
Learning Objective 2: Interpret key elements of genetic test reports, including variant classification, variant allele frequency, gene penetrance, biomarkers, and clinical actionability.
Learning Objective 3: Identify guideline-based criteria for germline genetic testing in men with prostate cancer. Understand the clinical implications of genetic findings for prostate cancer screening, risk stratification, and management of both localized and advanced disease.
Learning Objective 4: Describe the genetic basis, clinical presentation, testing indications, and cancer risks associated with hereditary kidney cancer syndromes. Understand how specific genetic alterations inform surveillance and treatment strategies in syndromes such as von Hippel-Lindau (VHL) and hereditary leiomyomatosis and renal cell cancer (HLRCC).
Learning Objective 5: Recognize the genetic basis, tumor characteristics, and associated cancer risks of Lynch syndrome, and apply this knowledge to optimize the evaluation and management of patients with upper tract urothelial carcinoma.
Of Interest To
FellowsResidents
